Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Serial assessment of ventricular function by means of radionuclide angiography was performed in 50 patients with malignant neoplasms who received either 4'-epidoxorubicin or mitoxantrone for longer than 3 months. In 9 of 30 patients given 4'-epidoxorubicin, a decrease of greater than or equal to 10% in the left ventricular ejection fraction (LVEF) was documented at doses of 143-1200 mg/m2. Two patients developed clinical signs of cardiotoxicity at a dose of greater than 1000 mg/m2. In 6 of 20 patients given mitoxantrone a decrease of greater than or equal to 10% in the LVEF occurred at doses of 26-98 mg/m2.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000790:Angiocardiography; D000880:Anthraquinones / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D004317:Doxorubicin / Q000627:therapeutic use* / Q000633:toxicity; D015251:Epirubicin; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone; D009369:Neoplasms / Q000188:drug therapy*; D011877:Radionuclide Imaging; D013318:Stroke Volume / Q000187:drug effects
D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D015251:Epirubicin; D004317:Doxorubicin; D008942:Mitoxantrone